Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a new study into the longer-term damage amongst patients recovering from COVID-19, DPAG Research Fellow Dr James Grist of the Tyler Lab has been running a novel scanning technique that shows a dramatic decrease in the ability of the lungs to diffuse gas in to the blood stream after COVID infection. This work may shed light on the problem of breathlessness after COVID infection and help guide us in understanding therapeutic selection and efficacy.

Scarred lungs compared with healthy lungs show much larger areas of darkness, representing parts of the lungs that are having difficulty transporting oxygen into the blood stream. © University of Oxford

 

Our lightbulb moment was when we first reconstructed the data from post-COVID patients and saw the extent of the damage that can be caused by the disease, in otherwise healthy-looking lungs.
- Dr James Grist

Many patients of COVID-19 continue to remain short of breath following treatment, even after discharge. A new study from collaborative teams in Oxford and Sheffield Universities is the first in Europe to use hyperpolarised xenon gas with MRI scanning to identify previously unseen damage to lung function as patients recover from COVID-19 that are not picked up by conventional scans.

Hyperpolarised xenon MRI is unique in its ability to measure gas transfer in the lungs with imaging and identify where the damage caused by COVID-19 pneumonia has occurred. The technique uses lasers to temporarily increase the signal available from Xenon and thus enable imaging in the MRI scanner.

Early data analysed by DPAG’s Dr James Grist, who has been running the scans of COVID-19 patients at the Churchill Hospital, shows weakened lung function in all study participants, whereas strikingly this damage to lungs is not visible on a standard MRI or CT scan. According to Dr Grist: “The conventional imaging (CT) of these patients was clear, and described as ‘healthy’, but our technique showed up some serious problems in gas transport.” 

The data suggests that the ability to transfer oxygen from the lungs into the blood stream when breathing is visibly impaired for some time, even after hospital discharge following COVID-19 pneumonia. This ultimately may be an explanation for some patients experiencing persistent symptoms even if standard GP and hospital tests return normal results.

The research team, led by Professor Fergus Gleeson from Oxford’s Department of Oncology and Professor Jim Wild from the University of Sheffield Medical School, have been working initially with a group of 40 patients from Oxford and Sheffield over the next six months. The striking early results have prompted discussions to expand the study to involve more patients in the community and thus identify the overall prevalence of lung damage.

Dr James Grist said: “We are really interested to see if this damage persists over time, or if it is just a transient effect. We’ll use this technology to help understand the prevalence of gas transport deficits in many more patients post-COVID.”

 

The study is funded by the NCIMI and the University of Oxford, and supported by the NIHR Oxford Biomedical Research Centre. It will be linked to the big national clinical follow-up study PHOSP-COVID.

Those interested in this study can contact ncimi@oncology.ox.ac.uk.

 

These early results have been covered by the BBC.

Similar stories

REF 2021 results

DPAG researchers showcased at premier European Society of Cardiology meeting

DPAG scientists across four research groups were highlighted at the major annual European Society of Cardiology basic science conference (FCVB 2022). Congratulations are in order for Dr KC Park on receiving the Young Investigator Award and to Dr Elisabetta Gamen on winning the Moderated Poster Prize.

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.

DPAG Postdoctoral Researcher acknowledged for developmental and cell biology research

Dr Matthew Stower was selected to give an oral presentation of his work and his abstract won the second prize at the Joint Spring Meeting of the British Society for Developmental Biology (BSDB) and the British Society for Cell Biology (BSCB).

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.